Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

SIMM and Crown Bioscience Reach Landmark Agreement

Published: Friday, November 29, 2013
Last Updated: Friday, November 29, 2013
Bookmark and Share
Agreement to develop world-leading mouse clinical center and largest annotated PDX and translational oncology platform.

Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS) and Crown Bioscience, Inc., have announced that they have reached an agreement to form a strategic collaboration focused on translational oncology and to join forces to build a mouse clinical trial (MCT) center at Crown Taicang campus, Taicang, Jiangsu province, China --SIMM-Crown Mouse Clinical Trial Center, or SCMC.

This strategic partnership aims at building the world first and largest mouse clinical center featuring the largest and most advanced translational oncology platforms with fully annotated collections of patient derived xenograft (PDX) models.

The immediate focus of the Center will be to combine the existing model collections of both organizations (approaching a thousand) and build several thousand more new models focusing on major Asian cancer types, including liver (HCC), lung (NSCLC), gastric (GC) and colorectal (CRC) cancers.

With this joint effort, the Center will dramatically expand the combined operational capacity to support global translational oncology efforts, particularly mouse clinical trial (HuTrial™ platform) or co-trial, supporting cancer research communities, cancer hospitals and the pharmaceutical industry.

It will also utilize the strength of both organizations to advance PDX based translational oncology platforms, to advance our knowledge of cancer biology and to de-risk drug development.

In particular, the Center will be able to help accelerate the development of SIMM’s pipeline of novel and rich targeted oncology drug candidates by leveraging Crown’s advanced oncology discovery and translational capabilities, including proprietary HuPrime®1.0, 2.0, 3.0, HuKemia®, HuTrial™, HuSignature™ platforms.

The signing of the agreement was held at SIMM headquarter in Shanghai, China, where Dr. Jian Ding, Director General of SIMM, a renowned cancer pharmacologist, a member of Chinese Academy of Engineering, and the Center’s first President, represented SIMM and Dr. Jean-Pierre Wery, Crown’s President represented Crown Bioscience.

At the signing ceremony, Dr. Ding stated: “As the largest government-founded research institute focusing on drug development in China, SIMM aims at inventing more world-class drugs to benefit patients in China and worldwide. The premium oncology translational research platform based on PDX models will enable us to have a better understanding of our candidate drugs and to stratify the responsive subgroup patients for personalized therapy. SIMM is excited about the opportunity of building up a first class translation oncology center together with Crown to accelerate the development of precision medicines for oncology applications.”

Dr. Wery commented at the ceremony: “Crown plays a leading role in providing cutting-edge translational platforms and cost effective drug discovery solutions for almost all top pharmaceutical companies worldwide. Crown is very happy to partner with SIMM, the premium drug discovery CAS institute in China, to offer the world with first class translational oncology services, and ultimately benefit cancer patients all around the world. This center will further strengthen Crown’s leading position as the oncology discovery and translational medicine partner in the global market”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Expands Cardiovascular and Metabolic Disease Capabilities
Company has announced Zhen Pang as scientific director.
Thursday, October 15, 2015
Crown Bioscience Brings Top Scientists Together
Experts to discuss best approaches to advance translational oncology.
Saturday, October 03, 2015
Crown Bioscience Strengthens Pre-Clinical Leadership Team with Senior Appointment
The company has appointed Laurie Heilmann as senior vice president.
Friday, July 03, 2015
Crown Bioscience Expands its Partnership with The National Resource Center for Mutant Mice
The expanded collaboration will focus on developing immuno-oncology mouse models and other disease-specific experimental models supporting translational medical research.
Friday, July 03, 2015
Crown Bioscience Acquires Molecular Response’s PDX Business
Company is acquiring all of Molecular Response’s existing PDX models.
Friday, February 13, 2015
Crown Bioscience Expands Operations and Re-Brands UK Site
Existing facility will become centre of excellence for hormonal oncology and step up European operations.
Friday, January 09, 2015
Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Bioscience President Honored in PharmaVOICE 100
Dr Jean-Pierre Wery is recognized for pioneering work in translational medicine, improving the efficiency of drug discovery and development.
Friday, August 01, 2014
Crown Reveals Strategy for Combined Drug-IR Therapy to Overcome Resistance
Novel strategies for combining drug therapy with irradiation to deliver new hope for overcoming resistance in the clinic.
Saturday, June 21, 2014
Crown Bioscience to Showcase Progression in Human Surrogate Trials
HuTrialTM demonstrates commitment to furthering preclinical understanding in order to improve personal care and increase patient recovery rates.
Wednesday, May 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
Crown Bioscience Announces Research Collaboration with the NRCMM
New collaboration aims to develop disease-specific experimental models for translational medical research.
Saturday, May 10, 2014
Crown Bioscience Enters Strategic Partnership with SNBL
Agreement’s initial focus is for SNBL to promote Crown services to its Japanese client base.
Friday, April 25, 2014
Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery
Size of collection allows for more informed preclinical decision making on prospective drug candidates.
Wednesday, April 23, 2014
Crown Bioscience Enter Into a Business Collaboration with Xstrahl Ltd
Development of radiation models of cancer will enable the discovery of more effective oncology therapies.
Tuesday, October 15, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos